Lenti-EGFRvIII CAR (scFv-BBζ, 3C10)-VP(VP-CAR-LC545)
The ready-to-use lentiviral particles of Lenti-EGFRvIII CAR (scFv-BBζ, 3C10)-VP is packaged using 3rd generation of lentiviral packaging system, in which the gene of CAR will be driven by a CMV promotor. The target gene of scFv (3C10)-41BB-CD3ζ packaged in lentiviral particles could be used for high efficency tranduction of T cells and stably integrated expression.
Specifications
Type of Therapeutics
Chimeric Antigen Receptor
Expression Cassette
scFv (3C10)-41BB-CD3ζ
Packaging System
Lentivirus
Targeting Diseases
Glioblastoma
Target
Introduction
EGFRvIII is a gain-of-function mutation that arises from genomic deletion of exons 2–7. This deletion leads to a ligand-independent receptor, although the constitutive activity of this receptor is lower than that of ligand-stimulated wtEGFR. Despite this sub-optimal activity, EGFRvIII imparts a significant growth advantage to HGG cells, especially in vivo.
Alternative Names
EGFRvIII; EGFR variant III
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Related Products
| Cat# |
Description |
| VP-CAR-LC696 |
Lenti-EGFRvIII CAR (scFv-CD28-41BB-CD3ζ, 139) Viral Particle |
| CAR-LC242 |
Anti-EGFRvIII (MR1) h(-CD28-CD3ζ) CAR, pCDCAR1 |
| CAR-LC055 |
Anti-EGFRvIII (3C10) h(41BB-CD3ζ) CAR, pCDCAR1 |
| VP-CAR-LC546 |
Lenti-EGFRvIII CAR (scFv-CD28-41BB-CD3ζ, 3C10) Viral Particle |
| VP-CAR-LC697 |
Lenti-EGFRvIII CAR (scFv-CD28-CD3ζ, 139) Viral Particle |
| CAR-LC221 |
Anti-EGFRvIII (139) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 |
| CAR-LC222 |
Anti-EGFRvIII (139) h(CD28-CD3ζ) CAR, pCDCAR1 |
| VP-CAR-LC714 |
Lenti-EGFRvIII CAR (scFv--CD28-CD3ζ, MR1) Viral Particle |
| CAR-LC056 |
Anti-EGFRvIII (3C10) h(CD28-41BB-CD3ζ) CAR, pCDCAR1 |
| CAR-LC271 |
Anti-EGFRvIII (139) h(41BB-CD3ζ, FKBP/FRB) Conditional CAR, pCDCAR1 |
Blastoma
Kits for CARs/TCRs Development 
Datasheet
Subscribe to Our Newsletter for Updates: